Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vascular diseases

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,302 result(s) found for: Vascular diseases. Displaying page 4 of 66.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-021162-30 Sponsor Protocol Number: Wil-24 Start Date*: 2011-12-20
    Sponsor Name:Octapharma AG
    Full Title: Prospective, Open-Label, Multi-Center, Phase III Clinical Study To Investigate The Efficacy And Safety Of Human Factor VWF/VIII Concentrate (Wilate®) In Subjects With Inherited Von Willebrand Disea...
    Medical condition: Surgery in Inherited Von Willebrand Disease (VWD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10047715 Von Willebrand's disease PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017753-34 Sponsor Protocol Number: CSLCT-BIO-08-52 Start Date*: 2010-07-09
    Sponsor Name:CSL Behring GmbH
    Full Title: A Phase III Open-label, Multi-centre Study to Assess the Pharmacokinetics, Efficacy, and Safety of Biostate® in Paediatric Subjects with von Willebrand Disease.
    Medical condition: Von Willebrand Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10047715 Von Willebrand's disease PT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-005569-58 Sponsor Protocol Number: BAY59-7939/17454 Start Date*: 2015-09-23
    Sponsor Name:Bayer AG
    Full Title: An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of Rivaroxaban to reduce the risk of major thrombotic vascular event...
    Medical condition: Peripheral artery disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10053375 Peripheral revascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) ES (Completed) HU (Completed) GB (Completed) FR (Completed) PT (Completed) SE (Completed) BE (Completed) BG (Completed) DK (Completed) DE (Completed) NL (Completed) PL (Completed) SK (Completed) LT (Completed) LV (Completed) RO (Completed) EE (Completed) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001478-14 Sponsor Protocol Number: 071301 Start Date*: Information not available in EudraCT
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A PROSPECTIVE, PHASE 3, OPEN LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH rVWF IN SEVERE VON WILLEBRAND DISEASE
    Medical condition: Hereditary severe von Willebrand Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10047715 Von Willebrand's disease PT
    19.0 10010331 - Congenital, familial and genetic disorders 10055168 Von Willebrand's factor deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) CZ (Completed) NL (Completed) ES (Completed) DE (Completed) FI (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-004868-69 Sponsor Protocol Number: AP7000_1-4002 Start Date*: 2005-03-07
    Sponsor Name:ZLB Behring LLC
    Full Title: Study of Safety and Efficacy of Antihemophilic Factor / von Willebrand Factor Complex (Humate-P®) Using Individualized Dosing in Pediatric and Adult Surgical Subjects with von Willebrand’s Disease
    Medical condition: Von Willebrand’s disease (VWD) is a common hereditary bleeding disorder. The impaired formation and adhesion of the initial platelet plug is reflected in the prolonged skin bleeding time. In addit...
    Disease: Version SOC Term Classification Code Term Level
    7.1 10047715 LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-001383-23 Sponsor Protocol Number: PROWILL Start Date*: 2006-06-30
    Sponsor Name:FONDAZIONE CENTRO EMOFILIA E TROMBOSI ANGELO BIANCHI BONOMI
    Full Title: Efficacy, safety and pharmaco-economic assessment of secondary long term prophylaxis with highly purified, standardized, doubly virus inactivated FVIII/VWF concentrates in patients with severe, inh...
    Medical condition: patients with severe inherited VWD unresponsive to DDAVP and with frequent bleedings
    Disease: Version SOC Term Classification Code Term Level
    8.1 10047715 Von Willebrand's disease PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000664-85 Sponsor Protocol Number: 8VWF03 Start Date*: 2006-12-19
    Sponsor Name:Bio Products Laboratory
    Full Title: An Open Multi-centre Study to Investigate the Safety and Efficacy of OPTIVATE®, a High Purity, Dual Inactivated Factor VIII and von Willebrand Factor Concentrate, in Patients with von Willebrand Di...
    Medical condition: von Willebrand disease
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000663-28 Sponsor Protocol Number: 8VWF01 Start Date*: Information not available in EudraCT
    Sponsor Name:Bio Products Laboratory
    Full Title: An open multi-centre study in patients with von Willebrand Disease to investigate the pharmacokinetics, efficacy and safety of Optivate, a high purity, dual inactivated Factor VIII and Von Willebra...
    Medical condition: von Willebrands Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047715 Von Willebrand's disease LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Ongoing) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017301-11 Sponsor Protocol Number: CSLCT-BIO-09-64 Start Date*: 2010-09-20
    Sponsor Name:CSL Behring GmbH
    Full Title: An Open-Label, Multi-Centre Extension Study to Assess the Efficacy and Safety of Biostate® in Paediatric, Adolescent, and Adult Subjects with Von Willebrand Disease who Completed Clinical Studies C...
    Medical condition: Von Willebrand's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10047715 Von Willebrand's disease PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) PL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012086-66 Sponsor Protocol Number: T05018-1001 Start Date*: 2009-12-01
    Sponsor Name:Grifols Inc
    Full Title: A Phase 1/2a, Open Label, Dose Escalation, Safety Study of Intra-thrombus Plasmin (Human) Administration in Acute, Middle Cerebral Artery, Ischemic Stroke
    Medical condition: Thrombus in acute ischemic stroke of the middle cerebral artery
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10008190 Cerebrovascular accident PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed) SK (Completed) AT (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2014-001319-38 Sponsor Protocol Number: MW051 Start Date*: 2015-09-24
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Monocenter prospective open single-arm phase IV study of the effects of hawthorn extract WS® 1442 on arterial micro-vascular structure and macro-vascular function, persistance and erectile functio...
    Medical condition: Underlying cardiovascular disease
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003376-20 Sponsor Protocol Number: 709/07 Start Date*: 2008-09-23
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: ANTITHROMBOTIC THERAPY IN THE DIABETIC PATIENT: STUDY ON THE EFFECT ON PLATELET FUNCTIONALITY OF A GREATER DOSAGE OF ASPIRIN OR THE ASSOCIATION OF LOW DOSES OF ASPIRIN PLUS SELECTIVE INHIBITOR OF ...
    Medical condition: PRIMARY PREVENTION ON MELLITUS DIABETES NIDDM
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061815 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003575-38 Sponsor Protocol Number: 071101 Start Date*: 2015-01-07
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A PHASE 3 PROSPECTIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF rVWF WITH OR WITHOUT ADVATE IN ELECTIVE SURGICAL PROCEDURES IN SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE
    Medical condition: Hereditary severe von Willebrand Disease in adult patients who will undergo major and minor elective surgical procedures
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004850 10055168 Von Willebrand's factor deficiency LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) IT (Completed) CZ (Completed) GB (Completed) NL (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002675-17 Sponsor Protocol Number: TIGER-BVS Start Date*: 2014-05-30
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Ticagrelor and absorb bioresorbable vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization
    Medical condition: Chronic total coronary occlusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-004600-17 Sponsor Protocol Number: T21 Start Date*: Information not available in EudraCT
    Sponsor Name:Royal College of Surgeons in Ireland
    Full Title: The use of Sildenafil in Neonates with Down Syndrome to Reduce Pulmonary Vascular Resistance.
    Medical condition: to assess the impact of oral sildenafil administration on echocardiography measurements of pulmonary vascular resistance in neonates with Down Syndrome without Congenital Heart Disease.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10022891 - Investigations 10067285 Vascular resistance pulmonary increased PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002277-35 Sponsor Protocol Number: AC16093 Start Date*: 2017-06-01
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: LACunar Intervention (LACI-2) Trial-2: Assessment of safety and efficacy of cilostazol and isosorbide mononitrate to prevent recurrent lacunar stroke and progression of cerebral small vessel disease.
    Medical condition: lacunar (small vessel) ischaemic stroke
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10071043 Basal ganglia stroke PT
    20.0 10029205 - Nervous system disorders 10068644 Brain stem stroke PT
    20.0 10029205 - Nervous system disorders 10023987 Late effects of cerebrovascular disease LLT
    20.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    20.0 10029205 - Nervous system disorders 10042244 Stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2007-001557-26 Sponsor Protocol Number: CV185-048 Start Date*: 2008-04-29
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: Apixaban Versus Acetylsalicyclic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double Blind Trial ...
    Medical condition: Patients with atrial fibrillation and at least one additional risk factor for stroke who have failed or are unsuitable for vitamin K antagonist therapy.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10042244 Stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) SE (Completed) BE (Completed) DE (Completed) FI (Completed) ES (Completed) DK (Completed) CZ (Completed) AT (Completed) GR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005980-26 Sponsor Protocol Number: MAAS Start Date*: 2012-07-04
    Sponsor Name:
    Full Title: Metformin and sitagliptin in patients with impaired glucose tolerance and a recent TIA or minor ischemic stroke - a multicenter, randomized, open-label phase II trial
    Medical condition: Stroke Transient ischemic attack Impaired glucose tolerance
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10042244 Stroke LLT
    14.1 10027433 - Metabolism and nutrition disorders 10052426 Glucose intolerance LLT
    14.1 10029205 - Nervous system disorders 10055221 Ischemic stroke LLT
    14.1 10029205 - Nervous system disorders 10044391 Transient ischemic attacks LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023979-25 Sponsor Protocol Number: 2010/353 Start Date*: 2011-01-03
    Sponsor Name:Department of Nephrology
    Full Title: Role of renal and systemic vascular resistance for progression of chronic kidney disease
    Medical condition: We want to investigate whether increased vasodilitation ( angiotensin converting enzyme inhibitor and calcium channel blocker) compared to standard treatment ( beta-blocker and angiotensin convert...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10047065 - Vascular disorders 10063097 Peripheral vasodilatation LLT
    13.1 10047065 - Vascular disorders 10047141 Vasodilatation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-009956-20 Sponsor Protocol Number: ICG-REG_01 Start Date*: 2009-05-29
    Sponsor Name:Free State of Bavaria rep. by the Univ. of Regensburg, rep. by the Regensburg Univ. Hospital
    Full Title: Prospective, randomized, controlled, mono-centric, two-armed, single-blinded pilot study for the treatment of venous and capillary vascular malformations by Indocyanine Green-augmented laser therapy
    Medical condition: venous and capillary vascular malformations
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10047091 Vascular malformations and acquired anomalies HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 07:30:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA